WO2024246657 - METHOD FOR CONJUGATION AND PURIFICATION OF ANTIBODY DRUG CONJUGATE
National phase entry is expected:
Publication Number
WO/2024/246657
Publication Date
05.12.2024
International Application No.
PCT/IB2024/054797
International Filing Date
17.05.2024
Title **
[English]
METHOD FOR CONJUGATION AND PURIFICATION OF ANTIBODY DRUG CONJUGATE
[French]
PROCÉDÉ DE CONJUGAISON ET DE PURIFICATION D'UN CONJUGUÉ ANTICORPS-MÉDICAMENT
Applicants **
INTAS PHARMACEUTICALS LTD.
Corporate House, Near Sola Bridge,
S. G. Highway, Thaltej, Ahmedabad,
Gujarat 380054, IN
Inventors
JOGLEKAR, Tushar
Intas Pharmaceuticals Limited – Biopharma Division,
Plot No: 423/P/A/GIDC, Vill: Moraiya
Sarkhej-Bavla Highway, Ta:Sanand,
Ahmedabad.
Gujarat 382213, IN
KUMAWAT, Rakesh
Intas Pharmaceuticals Limited – Biopharma Division,
Plot No: 423/P/A/GIDC, Vill: Moraiya
Sarkhej-Bavla Highway, Ta:Sanand,
Ahmedabad.
Gujarat 382213, IN
JOSHI, Kopal
Intas Pharmaceuticals Limited – Biopharma Division,
Plot No: 423/P/A/GIDC, Vill: Moraiya
Sarkhej-Bavla Highway, Ta:Sanand,
Ahmedabad.
Gujarat 382213, IN
HARER, Amol
Intas Pharmaceuticals Limited – Biopharma Division,
Plot No: 423/P/A/GIDC, Vill: Moraiya
Sarkhej-Bavla Highway, Ta:Sanand,
Ahmedabad.
Gujarat 382213, IN
MONDAL, Sumantra
Intas Pharmaceuticals Limited – Biopharma Division,
Plot No: 423/P/A/GIDC, Vill: Moraiya
Sarkhej-Bavla Highway, Ta:Sanand,
Ahmedabad.
Gujarat 382213, IN
DESHPANDE, Pratik
Intas Pharmaceuticals Limited – Biopharma Division,
Plot No: 423/P/A/GIDC, Vill: Moraiya
Sarkhej-Bavla Highway, Ta:Sanand,
Ahmedabad.
Gujarat 382213, IN
ADHIKARY, Laxmi
Intas Pharmaceuticals Limited – Biopharma Division,
Plot No: 423/P/A/GIDC, Vill: Moraiya
Sarkhej-Bavla Highway, Ta:Sanand,
Ahmedabad.
Gujarat 382213, IN
Priority Data
202321036862
29.05.2023
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
IP India
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 938 | |
| EPO | Filing, Examination | 6459 | |
| Japan | Filing | 532 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 2635 |
Total: 11139 USD
Abstract[English]
The present invention relates to the method for conjugation and purification of antibody drug conjugate wherein, the method controls drug to antibody ratio (DAR) and species distribution of antibody drug conjugate, such as Trastuzumab emtansine. The method of the present invention involves conjugation reaction controlled using static mixer and hydrophobic interaction chromatography (HIC) operated in flow through mode.[French]
La présente invention concerne le procédé de conjugaison et de purification d'un conjugué anticorps-médicament, le procédé régulant le rapport médicament sur anticorps (DAR) et la distribution d'espèces du conjugué anticorps-médicament, tel que le trastuzumab emtansine. Le procédé de la présente invention implique une réaction de conjugaison contrôlée à l'aide d'un mélangeur statique et d'une chromatographie d'interaction hydrophobe (HIC) actionnée en mode d'écoulement.